Your Shopping Cart
By using this site you agree to our use of cookies. Please refer to our privacy policy for more information. Close
McNeil recalls children’s BENADRYL Allergy FASTMELT tablets
- Date: December 09, 2010
- Source: Admin
The recall initiative by McNeil
McNeil Consumer Health care, Division of McNeil –PPC, Inc., in consultation with the U.S Food and Drug Administration (FDA) has recalled certain products. This is a voluntary recall of the following products:
All product lots of Children's BENADRYL® Allergy FASTMELT® Tablets (in Cherry and Grape Flavors) distributed in the United States, Belize, Barbados, Canada, Puerto Rico, St. Martin, and St. Thomas.
All product lots of Junior Strength MOTRIN® caplets , 24 count, distributed in the U.S
The recall was initiated at the wholesale and retail level. The company said no action was required on the part of consumers or health care providers. Consumers could continue using the products. The recall was decided upon after a review under the company’s Comprehensive Action plan brought to light, inadequacies in the development of manufacturing process. There is no indication that the recalled products do not meet quality standards. The recall has not been triggered by adverse events.
Regulations
Manufacturers or distributors of a product voluntarily carry out most recalls of products regulated by FDA. A manufacturer / distributor may come to know that one of its products is defective and recall it spontaneously. Alternatively, the FDA may infer that the product is defective and tell the manufacturer / distributor concerned to recall the product. Usually, the company will comply. If it does not, the FDA can seek legal action under the FD&C. Seizure of the stocked product, and/or injunction of the firm, including a court request for recall of the product are amongst the possible FDA actions. The joint effort of FDA and its regulated industries has proved successful over the years because neither of the two wants the consumers to suffer for a mistake they have not made.
FDA guidelines the companies should comply with while recalling defective products appear in Title 21 of the Code of Federal Regulations, Part 7. Accordingly, the FDA expects these firms to take full responsibility for product recalls, including follow-up checks to assure that recalls are successful. Companies should notify FDA when they initiate recalls and report the progress made on recalls to FDA. The guidelines categorize all recalls into Class I or Class II or Class III depending on the level of hazard involved. Class III recalls concern products that are unlikely to cause any adverse health reaction, but violate FDA labeling or manufacturing regulations. Examples might be a container defect (plastic material delaminating or a lid that does not seal); off-taste, color, or leaks in a bottled drink, and lack of English labeling in a retail food. The instant case involving McNeil Consumer Healthcare, qualifies as a Class III recall.
Example
McNeil Consumer Healthcare recalled three TYLENOL® Cold Multi-Symptom liquid products from wholesalers and retailers in consultation with the FDA for updating the labels. It was not driven by adverse effects. No action was required on the part of consumers or health-care providers. Consumers could continue using the product.
McNeil Consumer Health care, Division of McNeil –PPC, Inc., in consultation with the U.S Food and Drug Administration (FDA) has recalled certain products. This is a voluntary recall of the following products:
All product lots of Children's BENADRYL® Allergy FASTMELT® Tablets (in Cherry and Grape Flavors) distributed in the United States, Belize, Barbados, Canada, Puerto Rico, St. Martin, and St. Thomas.
All product lots of Junior Strength MOTRIN® caplets , 24 count, distributed in the U.S
The recall was initiated at the wholesale and retail level. The company said no action was required on the part of consumers or health care providers. Consumers could continue using the products. The recall was decided upon after a review under the company’s Comprehensive Action plan brought to light, inadequacies in the development of manufacturing process. There is no indication that the recalled products do not meet quality standards. The recall has not been triggered by adverse events.
Regulations
Manufacturers or distributors of a product voluntarily carry out most recalls of products regulated by FDA. A manufacturer / distributor may come to know that one of its products is defective and recall it spontaneously. Alternatively, the FDA may infer that the product is defective and tell the manufacturer / distributor concerned to recall the product. Usually, the company will comply. If it does not, the FDA can seek legal action under the FD&C. Seizure of the stocked product, and/or injunction of the firm, including a court request for recall of the product are amongst the possible FDA actions. The joint effort of FDA and its regulated industries has proved successful over the years because neither of the two wants the consumers to suffer for a mistake they have not made.
FDA guidelines the companies should comply with while recalling defective products appear in Title 21 of the Code of Federal Regulations, Part 7. Accordingly, the FDA expects these firms to take full responsibility for product recalls, including follow-up checks to assure that recalls are successful. Companies should notify FDA when they initiate recalls and report the progress made on recalls to FDA. The guidelines categorize all recalls into Class I or Class II or Class III depending on the level of hazard involved. Class III recalls concern products that are unlikely to cause any adverse health reaction, but violate FDA labeling or manufacturing regulations. Examples might be a container defect (plastic material delaminating or a lid that does not seal); off-taste, color, or leaks in a bottled drink, and lack of English labeling in a retail food. The instant case involving McNeil Consumer Healthcare, qualifies as a Class III recall.
Example
McNeil Consumer Healthcare recalled three TYLENOL® Cold Multi-Symptom liquid products from wholesalers and retailers in consultation with the FDA for updating the labels. It was not driven by adverse effects. No action was required on the part of consumers or health-care providers. Consumers could continue using the product.
Source:
Compliance Trainings
Sterile Filtration of Pharmaceutical Products - Validation and Regulatory Requirements
By - Roger Cowan
On Demand Access Anytime
By - Roger Cowan
On Demand Access Anytime
HVAC and GMP Environmental Control - for Pharmaceutical Cleanrooms
By - Roger Cowan
Live December 10, 2024
By - Roger Cowan
Live December 10, 2024
Extractables and Leachables in Early Phase Development
By - Wayland Rushing
On Demand Access Anytime
By - Wayland Rushing
On Demand Access Anytime
Processes & Effects of Immunogenicity to Biologics & the Screening Methodologies - 3 hour Virtual Training
By - Gwen Wise Blackman
On Demand Access Anytime
By - Gwen Wise Blackman
On Demand Access Anytime
Compliance Standards
Best Sellers
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
-
By: Miles HutchinsonAdd to CartPrice: $249
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
-
San Francisco, CA | Aug 6-7, 2020
-
Virtual Seminar | Jul 16-17, 2020
-
Virtual Seminar | Jun 18-19, 2020
-
Los Angeles, CA | Aug 20-21, 2020
-
Virtual Seminar | Jul 16-17, 2020
-
Virtual Seminar | Jun 25-26, 2020
-
Virtual Seminar | Jun 10, 2020
-
Virtual Seminar | Jun 3-4, 2020
-
Virtual Seminar | Jul 6-7, 2020
-
San Francisco, CA | Oct 22-23, 2020
-
Virtual Seminar | Jul 9-10, 2020
-
Virtual Seminar | Jun 3-4, 2020
-
Virtual Seminar | June 3-4, 2020
-
Miami, FL | Jul 29-31, 2020
-
Virtual Seminar | Jun 17, 2020
-
Provider: ANSIAdd to CartPrice: $142
- Add to Cart
- Add to Cart
- Add to Cart
-
Provider: ANSIAdd to CartPrice: $120
-
Provider: ANSIAdd to CartPrice: $250
-
Provider: SEPTAdd to CartPrice: $299
- Add to Cart
-
Provider: Quality-Control-PlanAdd to CartPrice: $37
- Add to Cart
-
Provider: At-PQCAdd to CartPrice: $397
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
You Recently Viewed